Berenson JR - Search Results

1

The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.

Andreu-Vieyra CV, Berenson JR. Andreu-Vieyra CV, et al. Among authors: berenson jr. Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614. Ther Adv Hematol. 2014. PMID: 25469210 Free PMC article. Review.

2

Supportive care in myeloma.

Berenson JR. Berenson JR. Clin Adv Hematol Oncol. 2004 Sep;2(9):569, 571. Clin Adv Hematol Oncol. 2004. PMID: 16163246 No abstract available.

3

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Berenson JR, et al. Cancer. 2005 Nov 15;104(10):2141-8. doi: 10.1002/cncr.21427. Cancer. 2005. PMID: 16206291 Free article. Clinical Trial.

4

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. Berenson JR, et al. Clin Cancer Res. 2007 Mar 15;13(6):1762-8. doi: 10.1158/1078-0432.CCR-06-1812. Clin Cancer Res. 2007. PMID: 17363530 Clinical Trial.

5

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R. Berenson JR, et al. Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8. Ann Hematol. 2008. PMID: 18463870 Clinical Trial.

6

NF-kappaB in the pathogenesis and treatment of multiple myeloma.

Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR. Li ZW, et al. Among authors: berenson jr. Curr Opin Hematol. 2008 Jul;15(4):391-9. doi: 10.1097/MOH.0b013e328302c7f4. Curr Opin Hematol. 2008. PMID: 18536579 Review.

7

A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.

Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA. Berenson JR, et al. Clin Cancer Res. 2009 Feb 1;15(3):1069-75. doi: 10.1158/1078-0432.CCR-08-1261. Clin Cancer Res. 2009. PMID: 19188182 Clinical Trial.

8

A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.

Waterman GN, Yellin O, Swift RA, Mapes R, Eades B, Ackerman E, Berenson JR. Waterman GN, et al. Among authors: berenson jr. Ann Hematol. 2011 Feb;90(2):193-200. doi: 10.1007/s00277-010-1052-8. Epub 2010 Sep 1. Ann Hematol. 2011. PMID: 20809423

9

Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.

Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Bolejack V, Nassir Y, Hilger JD, Sefaradi A, Shamouelian A, Swift RA. Berenson JR, et al. Am J Hematol. 2011 Jan;86(1):25-30. doi: 10.1002/ajh.21912. Am J Hematol. 2011. PMID: 21120861 Free article.

10

Updates in the treatment of multiple myeloma.

Berenson JR. Berenson JR. Clin Adv Hematol Oncol. 2012 Oct;10(10):667-9. Clin Adv Hematol Oncol. 2012. PMID: 23187773 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

285 results

Search Page